Then the SP will decline

Luckily the last interim results (the second set) was only a month ago and clearly stated the Longer the Exposure to SNT 5505 the great er the benefit..

So for the Phase II to not hit its Primary End Point would be diametrically opposed to the 2 previous updates..

Also in this very Announcement it said the FDA made their decision based on the Clinical Data and Data presented to Date.. so a very poor look for the FDA?

The old saying

If in doubt pull out ,,

plus SNT is not a one trick pony
SNT 9465 and the UK funded Phase II Parkinson Trial SNT 4728

First participant recruited to pioneering UK trial in global effort to tackle early causes of Parkinson’s

Share Share Share Share Share

• Clinical Neurology

Research

8 May 2025

A pioneering clinical trial for people with a sleep disorder who are at higher risk of developing Parkinson’s has recruited its first UK participant from the Discovery Cohort study at the Oxford Parkinson’s Disease Centre (OPDC)

Dr Karolien Groenewald with the first UK trial participant

Funded by the Parkinson’s Virtual Biotech, the trial is part of a global effort with Australian drug discovery company, Syntara. With sites in Australia and the UK, the partnership is focused on looking at the earliest causes and signs of Parkinson’s to uncover whether a potential treatment can reduce inflammation in the brain to hopefully protect brain cells from dying over time and slow down or stop the condition from developing.

The clinical trial involves 40 people with iRBD (idiopathic REM sleep behavior disorder), a diagnosed condition where people act out their dreams, sometimes multiple times a night, which is linked with an increased risk of developing Parkinson's disease. It will trial a potential treatment, known as SNT-4728.

Three quarters of the participants will receive the active medication and the remaining quarter will receive a placebo for 12 weeks. Brain scans will form a major part of the study to see what is happening deep within the brain, offering unprecedented insights into the early causes of Parkinson's and whether the potential treatment offers hope towards a way to delay or stop the onset of the condition